Through epigenetic silencing (e.g., promoter methylation) or genetic alterations (e.g., β2-microglobulin mutations), tumor cells substantially reduce their antigen-presenting capacity, preventing recognition of tumor-associated antigens by T cells [17]. Here, HLA-G is linked to neoplasm.